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Objectives: This study was designed to evaluate the psychometric features of the Persian version of the 
Fatigue Impact Scale (FIS-P) tool when used in Iranian MS patients. 
Methods: 140 MS patients and the equivalent number of healthy controls completed the following 
assessments: FIS-P, Fatigue Severity Scale (FSS), SF-36 questionnaire and the Mini-Mental State 
Examination (MMSE).  
Results: A significant inverse correlation between FIS and the quality of life (SF-36 assessment tool), as 
well as a positive and significant correlation with the FSS were noted. The Intraclass Correlation 
Coefficient (ICC) values for the inter-rater reliability for the physical, cognitive, and social sections and 
the whole questionnaire were 0.89, 0.86, 0.95 and 0.98, respectively. The FIS Persian version was shown 
to possess a high reliability (with a Cronbach’s alpha of 0.953). Likewise, the ICC values for the test-
retest reliability were 0.86, 0.87, 0.92 and 0.93 for the physical, cognitive, social subscales and the whole 
questionnaire, respectively. This suggested a high reliability for the FIS-P. 
Discussion: With a proper validity and reliability, the Persian-version of FIS retains the capability for 
being used in the assessment of fatigue and evaluation of the treatment and rehabilitation effects on 
fatigue-related symptoms among Persian-speaking patients with MS.  
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Introduction 
Multiple sclerosis (MS) is a challenging, 
progressive, and disabling neurological disease in 
young adults, mainly caused by autoimmune 
processes involving the myelin sheath. Depending 
on the location, size, and the time course of the 
sclerotic plaques and CNS lesions, the clinical 
manifestations of MS vary and may include motor, 
cerebellar, brain stem, sensory, visual, sphincteric, 
as well as cognitive insufficiencies and behavioral 
disorders (1). Fatigue is the most troublesome 
symptom and is a common complaint in MS patients 
(50-95%) (2-8), restricting patients’ work and social 
communications (4,9-17), activities of daily life and 
lifestyles (7,18,19), as well as affecting their mental 
and psychological wellbeing (20,21). According to 
the Multiple Sclerosis Council Practice Guidelines 
(1998), fatigue is defined as a subjectively perceived 
compromise in physical and or mental energy which 
interferes with common and desired activities 
(13,22,23). Given its unknown etiology, the 
assessment and management of fatigue seem to be 
difficult (24,25). Meanwhile, due to the importance 
of fatigue in patients’ functional and performance 
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status, and its widespread presence among MS 
patients, access to an accurate qualitative and 
quantitative fatigue assessment tool in the 
assessment and management of its symptom is 
required (7,26,27). Access to such a tool would 
enable clinicians and researchers to more accurately 
evaluate the effects of treatment interventions on 
fatigue control. To our knowledge, the translated and 
culturally adapted Persian version of the FIS has not 
yet been assessed for validity and reliability. The 
current study was conducted to assess this tool. Some 
of the most popular examples of such tools include: 
Fatigue Impact Scale (FIS) (28), Fatigue Severity 
Scale (FSS) (29), Modified Fatigue Impact Scale 
(MFIS) (29), Fatigue Descriptive Scale (FDS) (30), 
and the Daily Fatigue Impact Scale (DFIS) (31) tests 
which have been applied in MS patients. FIS and FSS 
are the most common and accurate tests used both in 
research and clinical settings worldwide (7,19).  
FIS (Fisk et al.) was first used to assess the impact 
of fatigue on daily life activities in MS patients 
(13,32,33). FIS is one of the most commonly used 
self-reported questionnaires with stronger 
psychometric features and a greater sensitivity, 
compared to other fatigue indicators (7). This tool 
was applied to evaluate fatigue in stroke, brain 
concussion, poliomyelitis, chronic fatigue syndrome, 
lupus and hepatitis patients (13,32,33). According to 
Fisk and his colleagues, the impact of fatigue on 
activities could be more sensitively assessed through 
FIS rather than simply asking the patients some 
fatigue-related questions (7). The test comprises 40 
questions assessing the fatigue-related limitations in 
the patients’ performance within the cognitive (10 
questions), physical (10 questions), and social 
activity (20 questions) domains (4,7,34). Studies 
carried out in different languages such as American 
English (correlation coefficient of 0.68-0.85) (7), 
Turkish (correlation coefficient of 0.93 and the 
Cronbach’s alpha of 0.97 and 0.91 for the whole test 
and sub-groups, respectively) (4), Hungarian 
(correlation coefficient of 0.85 and Cronbach’s α of 
0.98) (2) and French (Cronbach’s α of 0.80 and 
correlation coefficient of≥0.70) (35) have 
demonstrated a strong reliability and internal 
consistency for FIS. However, the purpose of this 
study is to determine whether measuring the effects 
of therapeutic interventions on fatigue control in MS 
patients may be possible using a validated 
questionnaire in a local language. The current 
investigation attempted to develop the Persian 
version of FIS (FIS-P) and to assess its validity and 
reliability when administered to Persian-speaking 
patients with MS. 
  
Methods 
Design of study - This cross-sectional investigation 
evaluated the psychometric features of the Persian 
equivalent of the FIS (FIS-P) in Persian-speaking 
MS patients. 
Preparing the FIS-P - Following an agreement with 
the institute where FIS originated (the French 
research institute of MAPI), the questionnaire was 
translated using the recommended forward-
backward translation method. The process of finding 
equivalents for obtaining a fatigue assessment tool 
which is reliable in terms of clarity and ease of 
understanding was carried out according to the PRO 
(Patient Reported Outcomes) measures during the 
whole process of forward translation, backward 
translation, and patient-testing (34). Throughout the 
preparation process, the institute of origin (MAPI) 
was updated with the progress reports. Finally, the 
translated questionnaire was pre-tested and tested on 
patients to ensure if the content was fully 
understandable and the equivalent terms used in the 
translated version were correctly perceived.  
Participants-This study enrolled 140 definite MS 
patients, as well as 140 healthy controls that were 
matched for age, sex, parental status and education. 
Patients were recruited amongst those registered and 
referred to the Tehran MS Society. This center is a 
governmental association considered as the referral 
center for MS patients across Iran (Table 1). Inclusion 
criteria in healthy subjects were: aged 18-50 and able 
to read and write with adequate cooperation. Exclusion 
criteria included: overt documented mental or 
psychiatric problems, regular hypnotics, anti 
depressive or antipsychotic use or addiction, history of 
chronic fatigue syndrome or symptoms of a chronic 
medical illness with a possible impact on fatigue and 
other fatigue-causing diseases. In the patient group, 
inclusion criteria were: definite MS patients according 
to McDonald 2010 criteria, aged 18-55, MMSE 
score≥21 and FSS≥4. The exclusion criteria in the 
patient group were: MS in relapse, taking anti-fatigue 
medications such as amantadine during the test period 
(unless discontinued at least 24 hours prior to the test) 
and any acute or chronic physical or mental illnesses. 
Cases and control subjects were enrolled in the study 
over a time course of recruitment. Based on such a 
consecutive sampling method, only the patients who 
fulfilled the inclusion criteria were recruited. Through 
this approach, a total of 140 cases as well as 140 
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control participants entered the study with their data 
finally analyzed. Our strategy was to enroll highly 
cooperative cases that fulfilled the inclusion criteria. 
The ethical protocol of this study was based on 
Declaration of Helsinki. The whole process was 
approved by the institutional review board and was 
assigned the ethics code (1/d/320/349,2011-2012). 
Informed written consent forms were signed by all 
participants prior to enrollment. Participants were 
reassured that all evaluation in this study is non-
invasive and causes no harm. Each subject could 
waive their continuation at any point during the study. 
Patients were informed about the significance of 
fatigue in their quality of life before being asked to 
participate in the study. All questionnaires and related 
documents remained anonymous throughout the 
study. Incomplete questionnaires were disregarded. 
Assessment Tools - Fatigue Impact Scale (FIS): This 
tool was primarily designed to assess the impact of 
fatigue on daily activities (Fisk, 1994). The scale 
consists of 40 items in 3 domains: physical (10 
items), cognitive (10 items) and social (20 items) 
(4,7,36). It is rated on a scale of 160 points, where 
higher scores indicate more fatigue (19). 
-Fatigue Severity Scale (FSS): This scale rates 
individual perception of fatigue using 9 questions 
(19). Participants rate the questions from 1 to 7, with 
grade 1 meaning strongly disagree and 7 meaning 
strongly agree. By totaling the grades, a higher score 
indicates a more significant effect of fatigue on the 
individual’s life. The validity and reliability of the 
Persian version of this scale was affirmed by 
Azimian et al. (5). - Short Form Health Survey (SF-
36): This tool was designed to measure the quality of 
life of patients and healthy individuals. SF-36 is 
currently the most widely used tool to measure 
quality of life (37). The validity and reliability of the 
Persian version of this scale was assessed by 
Montazeri and colleagues (38).  
-Expanded Disability of Status Scale (EDSS): This 
tool was designed by Kurtzke in 1983 to assess the 
degree of neurological impairment in MS patients. 
The scale is used to evaluate the pyramidal system, 
the cerebral, cerebellar, brain stem, sensory and 
visual systems. With a scale of 0-10, higher points 
indicate more disability. This assessment is 
performed by a neurologist (1,39). 
Test administration-Having received the MAPI 
institute’s approval, the Persian version of the tool 
was developed. The final version of this questionnaire 
is registered and currently available on MAPI 
Research Institute’s website at http://www.mapi-
trust.org. Following necessary explanations on the 
purposes of this research and how to answer the 
questions provided, the finalized questionnaires were 
administered to the enrolled subjects. In addition to 
FIS-P, other tools were administered. These were the 
SF-36 test to assess the participants QOL, the 
Expanded Disability Status Scale (EDSS) to measure 
the scale of participants’ disability and the MMSE 
questionnaire to screen for cognitive ability. 
Statistical analyses-The authors applied the Spearman 
correlation coefficients (for convergent validity), U 
Mann-Whitney (for divergent validity), Intraclass 
Correlation Coefficient (ICC) (for inter-rater 
reliability and test-retest reliability) and Cronbach's 
alpha coefficients (for internal consistency) in SPSS 
17.0 (Statistical Package for the Social Sciences). A 
p-value of less than 0.05 was considered significant. 
 
Results 
Demographic and clinical characteristics of the two 
study groups are summarized in table (1) and (2), 
respectively 
 
Table 1. Demographic data of patients with multiple sclerosis (n=140) and healthy adults (n=140) 
Patients with MS (n=140) Healthy adults (n=140) variable  N Percent  N Percent p-value 
Male 26 18.6  26 18.6 1 gender Female 114 81.4  114 81.4  
Single 44 31.4  50 35.7 0.448 Marital status Married 96 68.6  90 64.3  
≥12 class 21 15  20 14.3 0.368 
12-14 class 59 42.1  46 32.9  
16 class 51 36.4  64 45.7  Education 
≤18 class 9 6.4  10 7.1  
 
Most of the patients (n=115, 82.1%) had the 
relapsing-remitting type of the disease, while 7 
patients (5%), 17 patients (12.1 %) and 1 patient 
(0.7%), had the primary-progressive, secondary-
progressive and progressive-relapsing types, 
respectively. The FSS evaluation for fatigue 
revealed a score of 40.69, SD 15.34 for the patients 
and 26.15, SD 12.02 for the healthy group. 
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Table 2. Descriptive analysis of the medical features of the patients with multiple sclerosis (n=140) and healthy adults (n=140) 
Patients with MS (N=140) Healthy control (N=140) Variable M SD M SD 
MMSE 28.66 1.79 28.94 1.13 
FSS 40.69 15.34 26.15 12.02 
Disease duration (months) 67.62 61.7 - - 
EDSS 2.12 1.7 - - 
 
MMSE: Mini-Mental State Examination FSS: 
Fatigue Severity Scale EDSS: Expanded Disability 
Status Scale To determine the content validity, the 
FIS was administered to 10 occupational therapy 
faculty members. The content validity ratio (CVR) 
of each question was calculated. The average 
validity ratio of the questionnaire indicated the 
content validity index (CVI). The CVI for the whole 
questionnaire was 0.85.  
Since the data were not normally distributed 
according to the Kolmogorov-Smirnov test, the U 
Mann-Whitney was used to compare of the means of 
the two independent groups and to determine their 
divergent validity. The mean scores and the standard 
deviations of the two groups in each subscale and 
the whole questionnaire are shown in Table 3. 
According to such findings, for all subscales as well 
as for the global FIS-P score, there were significant 
differences between the MS patients and the healthy 
subject group.  
 
Table 3. The mean and standard deviation differences of Fatigue Impact Scale (FIS) scores of patients with multiple sclerosis and 
healthy adults 
Patients with MS Healthy adults Subscales M SD M SD p-value 
Physical 18.892 7.924 7.528 6.244 <0.001 
Cognitive 13.021 8.486 7.585 6.028 <0.001 
Social 31.105 14.167 14.844 10.364 <0.001 
Total 63.019 27.832 29.958 20.706 <0.001 
 
To study the convergent validity of FIS, Spearman’s 
correlation coefficient was used to find out how the 
scores obtained for the different subgroups of the 
questionnaire, and the total score of the 
questionnaire, were related to the different 
subgroups of the QOL test (SF-36) and the FSS 
questionnaire. These three parts, as well as the 
whole questionnaire, had an inverse and significant 
correlation with the QOL index and a positive and 
significant correlation with the FSS (Table 4). 
 
Table 4. Spearman’s correlation coefficient of the Persian version of the FIS with the SF-36 and FSS (convergent validity) 
FIS 
Physical Cognitive Social Total scales subscales 
r r r r 
Phys F -0.672** -0.372** -0.576** -0.603** 
Role P -0.628** -0.483** -0.626** -0.646** 
Pain -0.429** -0.391** -0.396** -0.445** 
Gen H -0.606** -0.489** -0.576** -0.615** 
Vitality -0.563** -0.531** -0.578** -0.623** 
Soc F -0.458** -0.411** -0.558** -0.539** 
Role E -0.444** -0.36** -0.565** -0.516** 
SF-36 
Men H -0.428** -0.538** -0.538** -0.567** 
FSS 0.682** 0.528** 0.636** 0.677** 
r= Correlation Coefficient Spearman's rho **Correlation is significant at the 0.01 level (2-tailed) 
 
The inter-rater reliability was determined by a 
random selection of 20 patients and was calculated 
by ICC. As outlined in table (5), the ICC values for 
physical, cognitive, and social domains, and the 
whole test, were 0.89, 0.86, 0.95, and 0.98, 
respectively. 
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Table 5. The inter-rater and test-retest reliability for the sub-groups of the FIS-P 
Subscales  ICC 95% Confidence interval p-value 
Inter-rater 0.89 0.74-0.95 <0.001 Physical Test-retest 0.86 0.69-0.94 <0.001 
Inter- rater 0.86 0.69-0.94 <0.001 Cognitive Test-retest 0.78 0.53-0.90 <0.001 
Inter- rater 0.95 0.89-0.98 <0.001 Social Test-retest 0.92 0.82-0.97 <0.001 
Inter- rater 0.98 0.97-0.99 <0.001 Total Test-retest 0.93 0.83-0.97 <0.001 
**ICC: Intra-class Correlation Coefficient 
 
The test-retest reliability was also determined by the 
random selection of 20 patients and was calculated 
by ICC. In Table 6, the ICC values for the physical, 
cognitive, and social sections and the whole 
questionnaire were 0.86, 0.78, 0.92, and 0.93, 
respectively. The Cronbach’s α was 0.953. This 
demonstrates a similarly high reliability for FIS-P 
(Table 5). 
 
Discussion 
In recent years, the use of optimized measurement 
scales to evaluate the effects of disease as well as the 
impact of treatment and rehabilitation on the outcome 
has gained much attention (40,41). Fatigue is one of 
the most common, and at the same time most 
disabling, symptoms of MS which negatively affects 
the patients’ quality of life (13). In order to provide 
patients with instructions and guide them through 
their fatigue management, a quantitative measure 
such as a valid questionnaire is needed (13,42). 
Furthermore, this quantification may assist health care 
professionals to efficiently plan treatment strategies to 
reduce fatigue-related symptoms (5). Nevertheless, 
such tools have mostly been used in clinical trials and 
research (33,36). Experienced translators contributed 
to the preparation of the final draft of the FIS-P. At 
the same time, we sought opinions from 20 MS 
patients to ensure the clarity of all translated terms 
and statements. For instance, in item number 10, 
despite the clarity of the term “clumsiness”, this term 
was changed to “slow and uncoordinated movement”.  
Since some participants, and females in particular, 
were unemployed, response to item 28 (financial 
resources) remained optional (there were 11 missing 
responses for this item). Moreover, as indicated by 
Fisk et al., the “sexual activity” item should also be 
adjusted to cultural frameworks (61 males waived 
responding to this item). Similar to what was 
observed by Fisk et al. (32) and Armutlu (4), this 
item was mainly answered by married individuals in 
our study. Our results are in line with those achieved 
in Mathiowetz’s research, which confirmed that 
although the structures of the FSS and FIS differ 
somewhat, and the two tests assess different aspects 
of fatigue (the severity of fatigue or its impact), they 
demonstrate a positive correlation (r=0.6). 
Furthermore, an average correlation is observed 
between the FIS and similar sub-groups of SF-36. 
Since these tools do not measure identical structures, 
a high correlation was not expected (7). Often, due 
to the severity of the disease, hand-tremors and 
nystagmus prevent the patients from completing the 
questionnaire. This gives rise to a need for a second 
party to read the questionnaire items to the patients 
and mark their responses. Because of this, the inter-
rater reliability needs to be evaluated. Despite this 
need, inter-rater reliability was not tested in other 
studies (2,4,7). The coefficients obtained for the ICC 
were 0.89, 0.86, 0.95, and 0.98 for the physical, 
cognitive, and social sub-scales and for the whole 
questionnaire, respectively. In studies by Mathiowetz 
(7) and Losonczi (2), a test-retest reliability 
assessment was carried out after an interval of six 
weeks and three months respectively (during which 
the retest was possibly affected by the progress of the 
disease). However, in our study, a one-week interval 
was used, with the results obtained conforming with 
those of Armutlu et al. (4) indicating ICC values of 
0.86, 0.78, 0.92, and 0.93 for the physical, cognitive, 
and social sub-groups, and the whole questionnaire, 
respectively. These values indicate an excellent 
reliability for FIS. Taken together, our ICC results 
demonstrated greater values than those obtained by 
Mathiowetz and Losonczi in the German version, 
while it was comparable with those of Armutlu et al. 
(2,4,7). Similar to the studies conducted by 
Mathiowetz, Armutlu, and Losonczi, our Cronbach’s 
α obtained for FIS-P (0.953) suggested a high 
internal consistency of FIS (2,4,7). Since we did not 
have an appropriate tool to assess the convergent 
validity of the P-FIS, we used the FSS and similar 
sub-groups of SF-36 to evaluate their validity. This 
can be considered as a limitation of the current 
study. Keeping in mind the fact that fatigue is a 
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common and disabling symptom in various chronic 
and disabling diseases, it is suggested that FIS be 
normalized in other populations. In addition, there 
seems to be a possibility for validating the use of the 
modified version of this questionnaire as the Persian 
version of the Daily Fatigue Impact Scale (D-FIS). 
This can be used to track the daily changes in terms 
of fatigue-related symptoms in the course of chronic 
diseases such as MS, Parkinson’s disease and 
hepatitis. In other words, one may utilize the 
currently validated FIS-P version in order to validate 
and standardize further questionnaires.  
Like many other investigations, the current study 
was subject to some shortcomings. These limitations 
included the lack of access to a larger sample size to 
assess test-retest and inter-rater reliability, and the 
paucity of similar reports which would have allowed 
for evidence comparison with our findings. We had 
no option but to assess the convergent validity of 
FIS-P using the validated Persian versions of FSS 
and SF-36. On the other hand, recruiting 140 MS 
patients and 140 healthy controls allowed us to 
efficiently assess the content validity and inter-rater 
consistency of the test. This has not been evaluated 
so far and thus can be considered as a strongpoint. 
 
Conclusion 
Given the strong psychometric features of FIS as 
compared with other tools, and based on the results 
of the current and similar studies on its proper 
validity and reliability, the Persian version of FIS 
(FIS-P) is suggested as a useful and suitable tool for 
assessing fatigue. This tool may also be applied to 
study the impact of treatment and rehabilitation 
interventions on fatigue in Persian-speaking MS 
patients. The use of the FIS-P questionnaire in local 
research centers is therefore recommended. 
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